目的 探討卡左雙多巴控釋片聯(lián)合多巴絲肼片治療帕金森病的臨床療效。方法 選取2014年1月—2016年1月眉山市人民醫(yī)院收治的帕金森患者123例為研究對(duì)象，所有患者隨機(jī)分為對(duì)照組（59例）和治療組（64例）。對(duì)照組口服多巴絲肼片，初始劑量為0.125 g/次，3次/d，服用1周后，根據(jù)個(gè)人病情逐漸增加治療量至最大劑量，并維持最大劑量不超過(guò)1.5 g/d（至少分3次服用）。治療組在對(duì)照組基礎(chǔ)上口服卡左雙多巴緩釋片，125 mg/次，1次/12 h。兩組患者均連續(xù)治療12個(gè)月。觀察兩組的臨床療效，比較兩組的帕金森病綜合評(píng)分量表（UPDRS）評(píng)分、簡(jiǎn)易智力狀態(tài)檢查量表（MMSE）評(píng)分和蒙特利爾認(rèn)知評(píng)估量表（MoCA）評(píng)分。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為71.19%、84.38%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組UPDRS各級(jí)評(píng)分均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組UPDRS評(píng)分明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組MMSE評(píng)分、MoCA評(píng)分均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 卡左雙多巴控釋片聯(lián)合多巴絲肼片治療帕金森病具有較好的臨床療效，可改善患者認(rèn)知功能，安全性較好，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Carbidopa and Levodopa Sustained-release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets in treatment of Parkinson's disease. Methods Patients (123 cases) with Parkinson's disease in Meishan City People's Hospital from January 2014 to January 2016 were randomly divided into the control group (59 cases) and the treatment group (64 cases). Patients in the control group were po administered with Levodopa and Benserazide Hydrochloride Tablets, starting dosage 0.125 g/time, three times daily, after 1 week, gradually increased the amount of treatment to the maximum dose and maintained the maximum dose of not more than 1.5 g/d (at least 3 times) according to the individual's condition. Patients in the treatment group were po administered with Carbidopa and Levodopa Sustained-release Tablets on the basis of the control group, 125 mg/time, 1 time/12 h. Patients in two groups were treated for 12 months. After treatment, the clinical efficacies were evaluated, and UPDRS scores, MMSE scores, and MoCA scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 71.19% and 84.38%, respectively, and there was difference between two groups (P < 0.05). After treatment, the various grade of UPDRS score in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, MMSE scores and MoCA scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Carbidopa and Levodopa Sustained-release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets has clinical curative effect in treatment of Parkinson's disease, can improve cognitive function, with good safety, which has a certain clinical application value.